Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

Hematopoietic Cell Transplant Access and Patient Diversity.

JAMA network open·2026
Same author

When remission alone might be good enough.

Blood advances·2026
Same author

When remission alone might be good enough.

Blood advances·2026
Same author

A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.

Blood advances·2025
Same author

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: May 26, 2026

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
13:16

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts

Published on: December 22, 2015

Can we build a better allograft?

Steven M Devine1

  • 1The Ohio State University Comprehensive Cancer Center.

Blood
|December 17, 2011
PubMed
Summary
This summary is machine-generated.

Disrupting CXCR4/CXCL12 signaling mobilizes hematopoietic stem and progenitor cells (HSPCs). This led to the FDA approval of AMD3100 for HSPC mobilization in lymphoma and myeloma patients treated with G-CSF.

More Related Videos

Modified Heterotopic Hindlimb Osteomyocutaneous Flap Model in the Rat for Translational Vascularized Composite Allotransplantation Research
09:36

Modified Heterotopic Hindlimb Osteomyocutaneous Flap Model in the Rat for Translational Vascularized Composite Allotransplantation Research

Published on: April 26, 2019

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

Related Experiment Videos

Last Updated: May 26, 2026

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
13:16

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts

Published on: December 22, 2015

Modified Heterotopic Hindlimb Osteomyocutaneous Flap Model in the Rat for Translational Vascularized Composite Allotransplantation Research
09:36

Modified Heterotopic Hindlimb Osteomyocutaneous Flap Model in the Rat for Translational Vascularized Composite Allotransplantation Research

Published on: April 26, 2019

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Disruption of the CXCR4/CXCL12 signaling pathway is implicated in hematopoietic stem and progenitor cell (HSPC) mobilization.
  • Granulocyte-colony stimulating factor (G-CSF) and other agents induce HSPC mobilization, partly through this pathway.

Discussion:

  • The CXCR4 antagonist AMD3100 targets this critical signaling pathway.
  • AMD3100's mechanism of action is crucial for its efficacy in HSPC mobilization.

Key Insights:

  • AMD3100 (plerixafor) is FDA-approved for HSPC mobilization.
  • This drug is used in combination with G-CSF for specific hematologic malignancies.

Outlook:

  • Further research may explore AMD3100 in other contexts or with novel agents.
  • Understanding CXCR4/CXCL12 signaling continues to advance stem cell mobilization strategies.